|Bid||95.03 x 100|
|Ask||99.70 x 200|
|Day's Range||96.64 - 97.88|
|52 Week Range||59.27 - 98.87|
|PE Ratio (TTM)||23.67|
|Earnings Date||Jan 25, 2018 - Jan 29, 2018|
|Forward Dividend & Yield||2.84 (2.91%)|
|1y Target Est||100.35|
Swing trades rely on inflection points in price to make buy decisions. Adding trading volume to the decision helps determine the intensity behind the move.
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
In 3Q17, Eli Lilly's (LLY) Olumiant (baricitinib) reported revenues of $16.2 million compared to $4.8 million and $1.9 million in 2Q17 and 1Q17, respectively.
- Phase 3 MURANO results presented for the first time today as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA - Prolonged ...
All the noise from Bitcoin may obscure new potential buy signals from big names like Microsoft, Intel, Fiat Chrysler, Biogen and AbbVie.
Marijuana industry in the US is still in its inception phase, but it’s growing, and the projections are very optimistic. This year, retail sales of medical and recreational weed in the US are expected to reach $6.5 billion and by 2021 the sales are forecasted to surge to $30 billion, as more states legalize medical […]
- Clinical results suggest that ibrutinib inhibits B cells and follicular helper T cells believed to play a critical role in treating chronic graft-versus-host disease (cGVHD), while preserving immune ...
- Nearly half of all R/R MCL patients in the pooled analysis were able to survive their disease at three years and more than one quarter of patients had no progression in their disease - Median PFS outcomes ...
- Follow-up data from RESONATE™-2 suggest long-term benefits of ibrutinib as a first-line therapy in CLL, via the longest patient-reported outcomes to date and a progression-free survival rate of 85 percent ...
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
The primary endpoints was achieved on patients affected with Waldenström's macroglobulinemia at the end of the Phase 3 of the clinical trial
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.